Deal of the Day — limited-time pharmacy picks!
Veenat 100mg Capsule

Veenat 100mg Capsule

Prescription requiredRx Required

Salt Composition: Imatinib

Expiry Date: 01/2028

Special offer

Price on Request

Price on Request

Inclusive of all taxes

▼

120 Capsule(s) In A Strip

About The Product

​Skin Cancer​

Description

Veenat 100mg Capsule belongs to a class of medication known as tyrosine kinase inhibitors as it contains Imatinib as an active ingredient. It is an anticancer medicine that is commonly prescribed to treat certain blood cancers like chronic myeloid leukemia & acute lymphocytic leukemia, and gastrointestinal stromal tumors.

It works as a specific inhibitor of several tyrosine kinase enzymes. After the oral administration, the effect of this medicine can be observed in 2-4 hours.

Uses

  • Blood cancer (Chronic myeloid leukaemia & acute lymphocytic leukemia)
  • Gastrointestinal stromal tumor

Side Effects

Like any other medicine, Veenat 100mg Capsule also has some adverse effects on the body, and most of them are manageable without special medical attention.
Some common side effects include:

  • Muscle cramp
  • Musculoskeletal (bone, muscle or joint) pain
  • Rash
  • Weight gain
  • Edema (swelling)
  • Nausea
  • Vomiting
  • Diarrhea
  • Fatigue
  • Abdominal pain
  • Bleeding
  • Breathing problems
  • Cough
  • Dizziness
  • Dry eye
  • Hemorrhage

Do not forget to discuss the risks and benefits of this medication with your doctor. Seek medical attention immediately in case of any severe issues.

How To Use

  • Take Veenat 100mg Capsule as prescribed by your doctor. Swallow it as a whole with water and don't chew, crush, or break it.
  • This tablet should be taken with or after food. Take it at the same time every day for effective results. Don't miss a dose or overdose the medicine.

How It Works

Veenat 100mg Capsule is an anti-cancer medication. It works by acting on a protein enzyme known as bcr-abl tyrosine kinase that is responsible for the uncontrolled growth of cancerous cells.

By inhibiting the action of this enzyme it effectively controls the growth and multiplication of cancer cells and slows down the progression of cancer.

Safety Advice

Alcohol
The interaction of alcohol with this drug is still unknown. It is advisable not to consume alcohol while taking Veenat 100mg Capsule.
Pregnancy
Do not take Veenat 100mg Capsule without consulting the doctor in case of pregnancy.
Breast Feeding
Veenat 100mg Capsule is unsafe to use during breastfeeding as it may cause toxicity to the baby. It is safe if prescribed.
Driving
Veenat 100mg Capsule may cause side effects such as dizziness or lack of concentration, which could affect your ability to drive. So it's better to avoid driving or operating heavy machinery.
Kidney
Consumption of Veenat 100mg Capsule should be avoided without informing the doctor if you have any kidney-related issues.
Liver
Consumption of Veenat 100mg Capsule should be avoided without informing the doctor if you have any liver-related issues.

FAQs

​Veenat 100mg is used to treat certain types of cancer, such as chronic myeloid leukemia, acute lymphocytic leukemia, and gastrointestinal stromal tumors.

References

  • ​Moen, M. D., McKeage, K., Plosker, G. L., & Siddiqui, M. A. A. (2007). Imatinib: a review of its use in chronic myeloid leukaemia. Drugs, 67(2), 299-320. https://pubmed.ncbi.nlm.nih.gov/17284091/
  • Sacha, T. (2014). Imatinib in chronic myeloid leukemia: an overview. Mediterranean journal of hematology and infectious diseases, 6(1), e2014007. https://pubmed.ncbi.nlm.nih.gov/24455116/
  • Manley, P. W., Cowan-Jacob, S. W., Buchdunger, E., Fabbro, D., Fendrich, G., Furet, P. ... & Zimmermann, J. (2002). Imatinib: a selective tyrosine kinase inhibitor. European journal of cancer, 38, S19-S27. https://pubmed.ncbi.nlm.nih.gov/12528769/
  • Iqbal, N., & Iqbal, N. (2014). Imatinib: a breakthrough of targeted therapy in cancer. Chemotherapy research and practice, 2014(1), 357027. https://pubmed.ncbi.nlm.nih.gov/24963404/
  • Deininger, M., Buchdunger, E., & Druker, B. J. (2005). The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood, 105(7), 2640-2653. https://pubmed.ncbi.nlm.nih.gov/15618470/
  • Peng, B., Lloyd, P., & Schran, H. (2005). Clinical pharmacokinetics of imatinib. Clinical pharmacokinetics, 44(9), 879-894. https://pubmed.ncbi.nlm.nih.gov/16122278/

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Read full medical disclaimer in Terms & Conditions
Magicine PharmacopyCopyright 2026